| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/02/2000 | EP0975783A2 Retroviral vectors, method for the production and the use thereof for gene transfer in cd4-positive cells |
| 02/02/2000 | EP0975782A1 Novel adenoviral vectors capable of facilitating increased persistence of transgene expression |
| 02/02/2000 | EP0975780A2 Il-2 gene expression and delivery systems and uses |
| 02/02/2000 | EP0975775A2 Regulatory system for inducible expression of genes with lambdoid promoters |
| 02/02/2000 | EP0975774A2 Bacterial plasmids |
| 02/02/2000 | EP0975773A1 Dna sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same |
| 02/02/2000 | EP0975764A1 A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin |
| 02/02/2000 | EP0975762A1 Type-1 ribosome-inactivating protein |
| 02/02/2000 | EP0975756A1 Fibroblasts with a foreign gene-containing composition for treating wounds |
| 02/02/2000 | EP0975754A1 Osteoprotegerin binding proteins and receptors |
| 02/02/2000 | EP0975751A1 A tm4sf human tumor-associated antigen |
| 02/02/2000 | EP0975750A2 Modified retinoblastoma tumor suppressor proteins |
| 02/02/2000 | EP0975666A2 Compositions and methods for the treatment and diagnosis of breast cancer |
| 02/02/2000 | EP0975654A1 Composition and method for treatment of cmv infections |
| 02/02/2000 | EP0975651A1 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease |
| 02/02/2000 | EP0975650A1 Oligomers which inhibit expression of collagen genes |
| 02/02/2000 | EP0975370A2 Composition and method for enhancing transport across biological membranes |
| 02/02/2000 | EP0975361A1 Methods of modulating immune coagulation |
| 02/02/2000 | EP0975355A2 Hexameric fusion proteins and uses therefor |
| 02/02/2000 | EP0975332A1 Improved methods of delivery using cationic lipids and helper lipids |
| 02/02/2000 | EP0975225A1 Fibrocyte-based cellular therapy formulations |
| 02/02/2000 | EP0839205B1 Liver-specific adenovirus expression vector |
| 02/02/2000 | CN1243544A Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons |
| 02/02/2000 | CN1243543A Purification and/or concentration of DNA by cross-flow filtration, separation of endotoxins from nucleic acid preparation |
| 02/01/2000 | US6020478 Human tumor-associated antigen |
| 02/01/2000 | US6020467 Antibodies against sulfotransferase |
| 02/01/2000 | US6020466 Myeloid cell leukemia associated gene mcl-1 |
| 02/01/2000 | US6020464 Isolated Smad protein |
| 02/01/2000 | US6020463 Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target |
| 02/01/2000 | US6020462 Nucleic acids encoding the hypoxia inducible factor-1 |
| 02/01/2000 | US6020319 Nucleic acid based immunotherapy of chronic hepatitis B infection |
| 02/01/2000 | US6020318 DNA methyltransferase genomic sequences and antisense oligonucleotides |
| 02/01/2000 | US6020199 Antisense modulation of PTEN expression |
| 02/01/2000 | US6020197 Neuroblasts are dependant upon about 1 to 100 ng/ml of bfgf for long term maintenance. |
| 02/01/2000 | US6020191 Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| 02/01/2000 | US6020189 Fibroblast growth factor homologous factors (FHFs) and methods of use |
| 02/01/2000 | US6020179 Nucleic acids encoding human tyrosine phosphatases |
| 02/01/2000 | US6020172 Nucleic acid delivery with ovine adenoviral vectors |
| 02/01/2000 | US6020161 PIGR-1, a member of immunoglobulin gene superfamily |
| 02/01/2000 | US6020160 For the treatment of infection, particularly bacterial infections. |
| 02/01/2000 | US6020158 Intracellular g-protein complex which mediates further intracellular signaling activities generally the production of second messengers such as cyclic amp (camp), phospholipase c, inositol triphosphate or ion channel proteins. |
| 02/01/2000 | US6020157 Polynucleotides encoding HFGAN72X receptor |
| 02/01/2000 | US6020152 Lymphocyte-associated cell surface protein |
| 02/01/2000 | US6020144 These organisms have evolved a sophisticated ability to infect a host and evade their host's immune defenses. |
| 02/01/2000 | US6020143 The invention is concerned with the identification, isolation and cloning of genes which are associated with alzheimer's disease. |
| 02/01/2000 | US6020142 Rath genes and polypeptides and methods for the treatment and diagnosis of immune disorders |
| 02/01/2000 | US6020135 Monitoring expression of these genes is used to provide indications of p53 status in a cell. such monitoring can also be used to screen for useful anti-cancer therapeutics, as well as for substances which are carcinogenic. |
| 02/01/2000 | US6020134 Method for diagnosing cancer via DNA hybridization |
| 02/01/2000 | US6019980 Nucleic acid respiratory syncytial virus vaccines |
| 02/01/2000 | CA2171982C Drug binding protein |
| 01/27/2000 | WO2000004183A1 Bone morphogenic protein |
| 01/27/2000 | WO2000004171A1 Treatment of diabetes with synthetic beta cells |
| 01/27/2000 | WO2000004157A2 Cloning and characterisation of novel mammalian peptidases |
| 01/27/2000 | WO2000004153A2 Repression of cell transformation with human pea3 |
| 01/27/2000 | WO2000004142A1 Mucins |
| 01/27/2000 | WO2000004141A2 Use of nucleic acid molecules as antiviral agents |
| 01/27/2000 | WO2000004135A2 Human scad-related molecules, scrm-1 and scrm-2 |
| 01/27/2000 | WO2000004051A2 Growth differentiation factor promoter and uses therefor |
| 01/27/2000 | WO2000004050A2 Neurotrophic growth factor |
| 01/27/2000 | WO2000004045A1 Axor10, a g-protein coupled receptor |
| 01/27/2000 | WO2000004037A1 Uncoupling protein 4 (ucp-4) and methods of use |
| 01/27/2000 | WO2000004034A2 Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages |
| 01/27/2000 | WO2000003738A1 Chelating systems for use in the delivery of compounds to cells |
| 01/27/2000 | WO2000003715A1 Treatment of dyskinesia |
| 01/27/2000 | WO2000003694A1 Charge reversal of polyion complexes |
| 01/27/2000 | WO2000003693A1 Survivin, and peptides thereof, as an anti-cancer vaccine |
| 01/27/2000 | WO2000003685A2 Nitrilase homologs |
| 01/27/2000 | WO2000003683A2 Liposomal encapsulated nucleic acid-complexes |
| 01/27/2000 | WO1999064604A3 Attenuated pestiviruses |
| 01/27/2000 | WO1999063115A3 Use of cathepsin s in the diagnosis and treatment of endometriosis |
| 01/27/2000 | WO1999063081A3 Ion channels |
| 01/27/2000 | WO1999061639A3 Retroviral delivery system |
| 01/27/2000 | WO1999061595A3 Adeno-associated viral vector-mediated expression of factor viii activity |
| 01/27/2000 | WO1999061589A3 Expansion of hematopoietic stem cells transduced with mdr-1 and methods of use thereof |
| 01/27/2000 | WO1999058564B1 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use |
| 01/27/2000 | WO1999057094A3 Perfluorinated esters of alkanoyl l-carnitine for the preparation of cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 01/27/2000 | WO1999054465A9 Gene encoding syntaxin interacting protein |
| 01/27/2000 | WO1999053959A3 Use of viral vectors for treatment of the injured peripheral and central nervous system |
| 01/27/2000 | WO1999053085A3 Selective regulation of adenovirus production |
| 01/27/2000 | WO1999052925A9 Programmed cell death and caspase-12 |
| 01/27/2000 | WO1999047152A3 Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells |
| 01/27/2000 | WO1999039735A9 Live vaccine for human immunodeficiency virus |
| 01/27/2000 | DE19833476A1 New genetically modified, adherently growing CD34-negative stem cells for transfer of gene therapy constructs for treatment of immunodeficiency and metabolic disorders |
| 01/27/2000 | DE19831043A1 Hemmung von Alopezie Inhibition of alopecia |
| 01/27/2000 | CA2337362A1 Cloning and characterisation of novel mammalian peptidases |
| 01/27/2000 | CA2335315A1 Nitrilase homologs |
| 01/27/2000 | CA2334161A1 Use of nucleic acid molecules as antiviral agents |
| 01/27/2000 | CA2334075A1 Bone morphogenic protein |
| 01/27/2000 | CA2333910A1 Neurotrophic growth factor |
| 01/27/2000 | CA2333853A1 Mucins |
| 01/27/2000 | CA2333471A1 Human scad-related molecules, scrm-1 and scrm-2 |
| 01/27/2000 | CA2332634A1 Repression of cell transformation with human pea3 |
| 01/26/2000 | EP0974668A1 Use of adenoviral E4 reading frames to improve expression of a gene of interest |
| 01/26/2000 | EP0974664A2 Human polypeptides and polynucleotides homolog to mouse testes-specific angiotensins converting enzyme |
| 01/26/2000 | EP0974660A1 Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| 01/26/2000 | EP0974659A2 Viral nucleotide sequences |
| 01/26/2000 | EP0974653A2 Human gastric cancer antigen gene and protein |
| 01/26/2000 | EP0974651A1 Physiologically active protein originating in mammals |
| 01/26/2000 | EP0974058A2 20 human secreted proteins |
| 01/26/2000 | EP0973927A1 Chimeric adenoviral coat protein and methods of using same |